Table 1.
Characteristic | No. (%) of studiesb |
---|---|
Journal impact factor | |
>50 | 19 (21) |
20-50 | 8 (9) |
5-20 | 65 (71) |
Article type | |
Original article | 54 (59) |
Research letter | 35 (38) |
Other (brief report or communication) | 3 (3) |
Study design | |
Retrospective observational | 83 (90) |
RCT | 5 (5) |
Prospective observational | 4 (4) |
Study center | |
Single-center | 51 (55) |
Multicenter | 39 (42) |
Unknown | 2 (2) |
Geographic area | |
Asia | 61 (66) |
Europe | 16 (17) |
North/South America | 10 (11) |
Multicountry | 5 (5) |
Sample size | |
20-100 | 36 (39) |
100-1000 | 45 (49) |
>1000 | 11 (12) |
Critically ill population | |
Subgroup | 64 (70) |
Full cohort | 28 (30) |
Critical illness categories | |
Patients admitted to the ICU | 23 (25) |
Severe (Chinese guidelines) | 25 (27) |
Severe (American guidelines) | 3 (3) |
Organ injury or dysfunction | 23 (25) |
Patients who died of COVID-19 | 18 (20) |
Research domain | |
Clinical characteristics | 52 (57) |
Risk factors | 29 (32) |
Treatment | 11 (12) |
COVID-19, coronavirus disease 2019; ICU, intensive care unit; RCT, randomized clinical trial.
Percentages may not total 100 because of rounding.